<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H97CF19BBE17448EFA9E9E52CC01373AC" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 1092 IH: Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-02-17</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1092</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230217">February 17, 2023</action-date><action-desc><sponsor name-id="M001163">Ms. Matsui</sponsor> (for herself and <cosponsor name-id="W000815">Mr. Wenstrup</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.</official-title></form><legis-body id="H94E7781CA8F34862B43B37D95882E179" style="OLC"><section commented="no" display-inline="no-display-inline" id="H7091126B10014A5190F1CEDE4267248E" section-type="section-one"><enum>1.</enum><header display-inline="yes-display-inline">Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023</short-title></quote> or the <quote><short-title>BENEFIT Act of 2023</short-title></quote>.</text></section><section commented="no" display-inline="no-display-inline" id="H78DA01CA53D9438C8CEC7979BFED507E" section-type="subsequent-section"><enum>2.</enum><header display-inline="yes-display-inline">Strengthening the use of patient-experience data within risk-benefit framework</header><text display-inline="no-display-inline">Section 569C of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-8c">21 U.S.C. 360bbb–8c</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="H1B24D2A230224C9D8288389E091F3F3B"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (a)(1)—</text><subparagraph commented="no" display-inline="no-display-inline" id="HC8A958AC136F4050A78214B4F9E41C09"><enum>(A)</enum><text display-inline="yes-display-inline">in subparagraph (A), by striking <quote>; and</quote> and inserting a semicolon;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HE4C9EC18E44C4E25832DA5E9E6AA2569"><enum>(B)</enum><text display-inline="yes-display-inline">in subparagraph (B), by striking the period and inserting <quote>; and</quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H29FC30CBA6C24BADBC584F0A73A37EC3"><enum>(C)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text><quoted-block display-inline="no-display-inline" id="HDBE4C0FD8A5C4AD0A8643AE88FBAFE3A" style="OLC"><subparagraph commented="no" display-inline="no-display-inline" id="HBE6B834DA7674A7F9A3B18373BABE061"><enum>(C)</enum><text display-inline="yes-display-inline">as part of the risk-benefit assessment framework in the new drug approval process described in section 505(d), considering patient experience data submitted by the medical product sponsor or another party.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H465655E629B44094B1E696810B306BC7"><enum>(2)</enum><text display-inline="yes-display-inline">in subsection (b)(1), by inserting <quote>, including a description of how such data and information were considered in the risk-benefit assessment described in section 505(d)</quote> before the period at the end.</text></paragraph></section></legis-body></bill> 

